NasdaqGM - Nasdaq Real Time Price USD

Voyager Acquisition Corp. (VACHW)

0.2101

-0.0099

(-4.50%)

At close: May 21 at 4:00:00 PM EDT

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical StudiesZURICH, May 20, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”), announced today the appointment of Rick Austin, Ph.D. as Chief Scientific Officer, effective May 1st. Dr. Austin brings more than 25 years of leadership ac

GlobeNewswire yesterday

VACH

VACHU

VACHW
-4.50%
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid TumorsZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ: VACH, "Voyager"), announced today a co-discovery alliance with OmniAb, Inc. (NASDAQ: OABI, “OmniAb”) for the development of a novel bispecif

GlobeNewswire 16 days ago

VACH

VACHU

VACHW
-4.50%
Veraxa to go public in $1.6bn SPAC deal with Voyager

Veraxa Biotech will gain access to $253m in cash from Voyager to advance its cancer drug pipeline.

Pharmaceutical Technology 28 days ago

GLDAF

VACHW
-4.50%
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with Strong and Differentiated Clinical ProfilesCompany Pursuing Multiple Strategic Partnerships and Licensing Opportunities in 2025 and 2026Transaction Values VERAXA at a Pre-money Equity Value of $1.3 BillionActively Working with Existing and New VERAXA Investors to Raise a Crossover F

GlobeNewswire 29 days ago

VACH

VACHU

VACHW
-4.50%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Voyager Acquisition Corp. (VACHW)

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

Veraxa to go public in $1.6bn SPAC deal with Voyager

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies